HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price

BiomX (NYSEAMERICAN:PHGE) had its target price hoisted by equities research analysts at HC Wainwright from $2.00 to $21.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for BiomX’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.53) EPS.

BiomX Stock Performance

Shares of PHGE stock opened at $0.63 on Tuesday. The stock has a market cap of $11.44 million, a price-to-earnings ratio of -0.20 and a beta of 1.27. BiomX has a 1 year low of $0.48 and a 1 year high of $4.99.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).